(98) evaluated the KRAS-IRF2-CXCL3-CXCR2 axis to identify the biological functions and mechanisms of oncogenic KRASG12D (KRAS*) in ICI resistance; the findings showed that resistance to anti-PD-1 therapy could be overcome in KRAS*-expressing CRC by enforced IRF2 expression or inhibition of CXCR2. This evidence concerns the gene KRAS and colorectal carcinoma.